Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands
Frans Opdam , Vincent O. Dezentje , Jan den Hartigh , Henk-jan Guchelaar , Trees Hessing , Tahar van der Straaten , Robert Vree , Erdogan Batman , Eduard Maartense , Carolien H. Smorenburg , Anneke Zeillemaker , J. A. C. Brakenhoff , Maartje Los , Philomeen Kuijer , Hein Putter , Anne-Sophie Dieudonné , Patrick Neven , Cornelis J. H. Van De Velde , J. W. R. Nortier , Hans Gelderblom
Background: Breast cancer patients with absent or reduced CYP2D6 activity may benefit less from tamoxifen treatment because of impaired biotransformation to the active metabolite endoxifen. We investigated whether a temporary one-step dose escalation of tamoxifen in CYP2D6 poor (PM) and intermediate metabolizers (IM) could increase endoxifen serum concentration to a similar level observed in CYP2D6 extensive metabolizers (EM) without increasing toxicity. Methods: From a prospective study population of early breast cancer patients using tamoxifen, 12 CYP2D6 poor and 12 intermediate metabolizers were selected and included in a one-step tamoxifen dose escalation study during two months. The escalation dose (120 mg maximum) was calculated by multiplying the individual’s endoxifen level divided by the median endoxifen concentration (33.7 nM) observed in CYP2D6 extensive metabolizers by 20 mg. Toxicity was assessed and all patients returned to the standard dose of 20 mg after two months. Results: Tamoxifen dose escalation in CYP2D6 poor and intermediate metabolizers significantly increased endoxifen concentrations (PMs: from 8.0 nM to 27.3 nM, p<0.001; IMs: from 17.8 nM to 30.3 nM, p=0.002) without increasing side effects. In intermediate but not in poor metabolizers dose escalation increased endoxifen to levels comparable with those observed in extensive metabolizers using tamoxifen 20 mg once daily (33.7 nM). Conclusions: CYP2D6 genotype and endoxifen guided tamoxifen dose escalation increased endoxifen concentrations without increasing short term side effects. Whether such tamoxifen dose escalation is effective and safe in view of long term toxic effects is uncertain and needs to be explored. Clinical trial information: NTR1509.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Takahiro Kogawa
2023 ASCO Annual Meeting
First Author: Stephanie L. Graff
2012 ASCO Annual Meeting
First Author: Bavanthi Balakrishnar
2024 ASCO Annual Meeting
First Author: Jennifer M Yeh